Skip to content

Neuronetics STIM Additional Paid-In Capital

Additional Paid-In Capital at other companies

LifeStance Health Group logo
LifeStance Health GroupLFST
$2.27B-0.1%
LBR
LB Pharmaceuticals Inc Common StockLBRX
$527.06M
CVRx, Inc. logo
CVRx, Inc.CVRX
$632.82M+2.0%
Stereotaxis logo
StereotaxisSTXS
$603.7M+5.8%
Neuropace, Inc. logo
Neuropace, Inc.NPCE
$573.52M+2.1%
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
$2.82B+11.3%

Other financials

Income statement

See full
Revenue$34.5M+7.8%
Gross profit$16.2M+2.6%
Operating income-$9.0M+18.3%
Net income-$10.8M+14.9%
EPS (diluted)-$0.16+23.8%

Balance sheet

See full
Cash & equivalents$13.2M-34.7%
Total debt$85.4M+3.5%
Total equity$13.3M-62.6%
Total assets$125.4M-11.7%

Cash flow

See full
Operating cash flow-$9.4M+44.6%
CapEx$197.0K-10.0%
Free cash flow-$9.6M+44.1%

Valuation

See full
Market cap$90.46M-56.2%
Enterprise value$162.64M-42.0%
P/S0.6×-1.3×

Profitability

See full
Gross margin48%-15.6pp
Operating margin-19.4%-6.9pp
Net margin-24.5%-8.7pp
FCF margin-9.4%-4.1pp

Returns & leverage

See full
Return on equity-152.4%-1.4pp
Debt / equity6.4×+4.1×
Current ratio1.7×-0.8×

Where this comes from

Reported directly by Neuronetics in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.

The official record: Neuronetics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Neuronetics's additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Neuronetics's additional paid-in capital?
Neuronetics (STIM) reported additional paid-in capital of $482.15M in Q1 2026.
How has Neuronetics's additional paid-in capital changed year-over-year?
Neuronetics's additional paid-in capital increased by 3.2% year-over-year, from $467.26M to $482.15M.
What is the long-term trend for Neuronetics's additional paid-in capital?
Over 5 years (2020 to 2025), Neuronetics's additional paid-in capital has grown at a 9.7% compound annual growth rate (CAGR), from $302.84M to $480.48M.
What does additional paid-in capital mean?
Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.